DYN Quote, Financials, Valuation and Earnings

Structure Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of --. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Structure Therapeutics, Inc.'s return on equity of -25.55%.

Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 116.4%. On the other hand Structure Therapeutics, Inc. has an analysts' consensus of $107.80 which suggests that it could grow by 17.34%. Given that Dyne Therapeutics, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Structure Therapeutics, Inc..

Dyne Therapeutics, Inc. has a beta of 1.319, which suggesting that the stock is 31.923% more volatile than S&P 500. In comparison Structure Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Structure Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Structure Therapeutics, Inc. quarterly revenues of --. Dyne Therapeutics, Inc.'s net income of -$108M is lower than Structure Therapeutics, Inc.'s net income of -$65.8M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Structure Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus -- for Structure Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of 9.72%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat MannKind Corp.'s return on equity of --.

Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 116.4%. On the other hand MannKind Corp. has an analysts' consensus of $9.61 which suggests that it could grow by 62.63%. Given that Dyne Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Dyne Therapeutics, Inc. is more attractive than MannKind Corp..

Dyne Therapeutics, Inc. has a beta of 1.319, which suggesting that the stock is 31.923% more volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.55%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Dyne Therapeutics, Inc.'s net income of -$108M is lower than MannKind Corp.'s net income of $8M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 62.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 5.81x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Avidity Biosciences, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -1398.33%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Avidity Biosciences, Inc.'s return on equity of -37.47%.

Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 116.4%. On the other hand Avidity Biosciences, Inc. has an analysts' consensus of $74.64 which suggests that it could grow by 2.61%. Given that Dyne Therapeutics, Inc. has higher upside potential than Avidity Biosciences, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Avidity Biosciences, Inc..

Dyne Therapeutics, Inc. has a beta of 1.319, which suggesting that the stock is 31.923% more volatile than S&P 500. In comparison Avidity Biosciences, Inc. has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.48%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avidity Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Avidity Biosciences, Inc. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Avidity Biosciences, Inc. quarterly revenues of $12.5M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Avidity Biosciences, Inc.'s net income of -$174.4M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Avidity Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 457.72x for Avidity Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of -- compared to Dyne Therapeutics, Inc.'s net margin of -45.06%. Dyne Therapeutics, Inc.'s return on equity of -64.85% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Dyne Therapeutics, Inc. has a consensus price target of $39.13, signalling upside risk potential of 116.4%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.74 which suggests that it could fall by -4.82%. Given that Dyne Therapeutics, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe Dyne Therapeutics, Inc. is more attractive than Sarepta Therapeutics, Inc..

Dyne Therapeutics, Inc. has a beta of 1.319, which suggesting that the stock is 31.923% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.

Dyne Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dyne Therapeutics, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Dyne Therapeutics, Inc. quarterly revenues are --, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Dyne Therapeutics, Inc.'s net income of -$108M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Dyne Therapeutics, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dyne Therapeutics, Inc. is -- versus 0.93x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.